In a recently published article in Nature Communications entitled “Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19“, co-author Nicholas Reynolds, fellow at the the La Trobe institute for Molecular Science in Melbourne, Australia, talks with Jan about the similarity between brain effects of long-term COVID and amyloid aggregates in Parkinson’s and Alzheimer’s patients. Their early basic-science studies could lead to better understanding and potential treatments.

A lay-person summary of their research can be found at the Institute for Public Accuracy.

Did you enjoy this story? Your funding makes great, local journalism like this possible. Donate here